Literature DB >> 1311751

Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use.

P Hambleton1.   

Abstract

The neurotoxins produced by Clostridium botulinum are the most potent acute toxins known and are the causative agents of the neuroparalytic disease botulism. The toxins act primarily at peripheral cholinergic synapses by blocking the evoked release of the neurotransmitter acetylcholine. There are seven distinct serotypes of toxin. All are polypeptides of Mr about 150 kDa that have similar structure and pharmacological action. In their most active forms the toxins exist as dichain molecules in which a heavy (H) chain is linked by disulphide bonding to a light (L) chain. The H chain is believed to be associated with the highly specific and avid binding of toxin to the motor nerve end plates and also with the process of internalisation of the toxin. The toxic activity appears to be associated with the L chain which blockades the calcium-mediated release of acetylcholine, probably by interfering at the molecular level with the mechanisms whereby neurotransmitter-containing vesicles merge with the plasmalemma. The type A toxin is now used therapeutically to treat a variety of conditions involving involuntary muscle spasm. The therapeutic toxin is a neurotoxin-haemagglutinin complex isolated from cultures of C. botulinum. A controlled manufacturing process has been developed for the therapeutic toxin which is specially formulated to give a freeze-dried product having good stability.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311751     DOI: 10.1007/bf00839205

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  22 in total

1.  The complete amino acid sequence of the Clostridium botulinum type A neurotoxin, deduced by nucleotide sequence analysis of the encoding gene.

Authors:  D E Thompson; J K Brehm; J D Oultram; T J Swinfield; C C Shone; T Atkinson; J Melling; N P Minton
Journal:  Eur J Biochem       Date:  1990-04-20

2.  Dose standardisation of botulinum toxin.

Authors:  N Quinn; M Hallett
Journal:  Lancet       Date:  1989-04-29       Impact factor: 79.321

3.  Inhibition of transmitter release by botulinum neurotoxin A. Contribution of various fragments to the intoxication process.

Authors:  B Poulain; J D Wadsworth; E A Maisey; C C Shone; J Melling; L Tauc; J O Dolly
Journal:  Eur J Biochem       Date:  1989-10-20

4.  Clostridium botulinum toxins: nature and preparation for clinical use.

Authors:  J Melling; P Hambleton; C C Shone
Journal:  Eye (Lond)       Date:  1988       Impact factor: 3.775

5.  A common subunit structure in Clostridium botulinum type A, B and E toxins.

Authors:  B R DasGupta; H Sugiyama
Journal:  Biochem Biophys Res Commun       Date:  1972-07-11       Impact factor: 3.575

6.  Pharmacologic weakening of extraocular muscles.

Authors:  A B Scott; A Rosenbaum; C C Collins
Journal:  Invest Ophthalmol       Date:  1973-12

7.  Interaction of botulinum type A, B and E derivative toxins with synaptosomes of rat brain.

Authors:  S Kozaki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1979-07       Impact factor: 3.000

8.  Localization of sites for 125I-labelled botulinum neurotoxin at murine neuromuscular junction and its binding to rat brain synaptosomes.

Authors:  J O Dolly; R S Williams; J D Black; C K Tse; P Hambleton; J Melling
Journal:  Toxicon       Date:  1982       Impact factor: 3.033

9.  Tetanus toxin: primary structure, expression in E. coli, and homology with botulinum toxins.

Authors:  U Eisel; W Jarausch; K Goretzki; A Henschen; J Engels; U Weller; M Hudel; E Habermann; H Niemann
Journal:  EMBO J       Date:  1986-10       Impact factor: 11.598

10.  Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves.

Authors:  J D Black; J O Dolly
Journal:  J Cell Biol       Date:  1986-08       Impact factor: 10.539

View more
  23 in total

Review 1.  Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion.

Authors:  Harald Brüssow; Carlos Canchaya; Wolf-Dietrich Hardt
Journal:  Microbiol Mol Biol Rev       Date:  2004-09       Impact factor: 11.056

2.  Botox induced muscle paralysis rapidly degrades bone.

Authors:  Sarah E Warner; David A Sanford; Blair A Becker; Steven D Bain; Sundar Srinivasan; Ted S Gross
Journal:  Bone       Date:  2005-09-26       Impact factor: 4.398

Review 3.  Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal.

Authors:  A Ferrari; M Manca; V Tugnoli; L Alberto
Journal:  Funct Neurol       Date:  2018 Jan/Mar

4.  Transient muscle paralysis degrades bone via rapid osteoclastogenesis.

Authors:  Antonios O Aliprantis; Marina Stolina; Paul J Kostenuik; Sandra L Poliachik; Sarah E Warner; Steven D Bain; Ted S Gross
Journal:  FASEB J       Date:  2011-11-28       Impact factor: 5.191

5.  Treatment of detrusor sphincter dyssynergia with baclofen and doxazosin.

Authors:  H Kilicarslan; S Ayan; H Vuruskan; G Gokce; E Y Gultekin
Journal:  Int Urol Nephrol       Date:  2006-11-23       Impact factor: 2.370

6.  [Botulinum toxin in dermatology].

Authors:  W G Philipp-Dormston
Journal:  Hautarzt       Date:  2014-02       Impact factor: 0.751

7.  Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease.

Authors:  G Neil Stowe; Peter Silhár; Mark S Hixon; Nicholas R Silvaggi; Karen N Allen; Scott T Moe; Alan R Jacobson; Joseph T Barbieri; Kim D Janda
Journal:  Org Lett       Date:  2010-02-19       Impact factor: 6.005

Review 8.  Cyclic Peptides that Govern Signal Transduction Pathways: From Prokaryotes to Multi-Cellular Organisms.

Authors:  Ryan W Mull; Anthony Harrington; Lucia A Sanchez; Yftah Tal-Gan
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

Review 9.  Botulinum toxin in clinical practice.

Authors:  A J Hughes
Journal:  Drugs       Date:  1994-12       Impact factor: 9.546

10.  Botulinum toxin a inhibits acetylcholine release from cultured neurons in vitro.

Authors:  P Ray
Journal:  In Vitro Cell Dev Biol Anim       Date:  1993-06       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.